An observational study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP and CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), sponsored by argenx. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by argenx · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany — 16 open to participants now, 18 under way, 7 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Germany.
Among the 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 10 that started in 2025, is one of 10 observational ones, reaches primary completion later than 15 of the 17 other live ones, and was the 33rd registered.
137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.
Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →16 of the 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany are open now. Recruiting first, the newest first:
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
University of Ulm · Sites in Germany
Ages 18+
argenx · Sites in Germany, United States, Argentina and 28 more countries
Ages 18+
Takeda · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 14
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 49 across 44 observational studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Median enrollment 106 across the 25 interventional studies, 79 across the 10 observational. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 35 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 9 studies filed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — fewer than ten, so there is no comparison to draw.
8 of the studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327114Phase 3Janssen Research & Development, LLCEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2026-12-15 |
| NCT06290141Phase 3SanofiA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2027-07-09 |
| NCT06920004Phase 3argenxA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | 2027-09 |
| NCT04280718argenxA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | 2027-04-30 |
| NCT07072676LMU KlinikumThe Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. | 2027-05-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.
As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.
Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
Adult CIDP participants considered to be initiating efgartigimod treatment per country-specific label for the treatment of CIDP
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Efgartigimod alfaStudies of Efgartigimod alfaEfgartigimod alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Hyaluronidase (human recombinant)Studies of Hyaluronidase (human recombinant)Hyaluronidase (human recombinant) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Efgartigimod treatment per country-specific label for the treatment of CIDP
Change in aINCAT score over time
The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).
Time frame: Up to 2 years and 3 months
Change in I-RODS score over time
Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP.
Time frame: Up to 2 years and 3 months
Change in grip strength over time
Time frame: Up to 2 years and 3 months
Change in EQ-5D value from index date over time
The EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome)
Time frame: Up to 2 years and 3 months
Not enrolling at this site — choose another above.
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →